BridgeMD
New treatment option for Dermatomyositis
Official title A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
ClinicalTrials.gov ID: NCT06698796
What this study is testing
What is Dazukibart?
Dazukibart is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for dermatomyositis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to understand how the study medicine, dazukibart, works in people with active idiopathic inflammatory myopathies (dermatomyositis [DM] or polymyositis [PM]). Idiopathic inflammatory myopathies are a group of disorders that show inflammation of the muscles used for movement.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participants that completed a qualifying study through Week 52.
You likely can't join if
- Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may...
- Previous administration with an investigational product (drug or vaccine) other than dazukibart in a qualifying study within 30 days (or as...
- Current use of any prohibited concomitant medication(s).
- Active bacterial, viral, fungal, mycobacterial or other infections.
- Ongoing adverse event in a qualifying study or the participant has met safety monitoring criteria in a qualifying study that have not resolved.
- Investigator site staff or sponsor employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and...
The study team makes the final eligibility decision.
Where it's taking place
- Glendale, Arizona, United States
- Allen, Texas, United States
- Houston, Texas, United States
- Beckley, West Virginia, United States
- SAN M. de Tucuman, Tucumán Province, Argentina
- Plovdiv, Bulgaria
- Hefei, Anhui, China
- Nanchang, Jiangxi, China
- Shanghai, Shanghai Municipality, China
- Kunming, Yunnan, China
- Beijing, China
- Debrecen, Hungary
- Ernākulam, Kerala, India
- Ramat Gan, Central District, Israel
- Bunkyo-ku, Tokyo, Japan
- Cuauhtémoc, Mexico City, Mexico
- Warsaw, Masovian Voivodeship, Poland
- Bialystok, Podlaskie Voivodeship, Poland
- Tainan, Taiwan
- Taipei, Taiwan
+ 1 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Glendale, Arizona, United States; Allen, Texas, United States; Houston, Texas, United States; Beckley, West Virginia, United States; SAN M. de Tucuman, Tucumán Province, Argentina; Plovdiv, Bulgaria and 15 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.